Abstract
To analyze the effect of radiation dose escalation to the primary tumor on local tumor control in definitive chemoradiation (dCRT) for patients with esophageal cancer. Patients with medically inoperable and/or irresectable esophageal carcinoma, referred for dCRT, were randomly assigned between a standard dose (SD) of 50.4 Gy/1.8 Gy for 5.5 weeks to the tumor and regional lymph nodes and a high dose (HD) up to a total dose of 61.6 Gy to the primary tumor. Chemotherapy consisted of courses of concurrent carboplatin (area under the curve 2) and paclitaxel (50 mg/m2) in both arms once a week for 6 weeks. The primary end point was local progression-free survival. Between September 2012 and June 2018, 260 patients were included. Squamous cell carcinoma (SCC) was present in 61% of patients, and 39% had adenocarcinoma (AC). Radiation treatment was completed by 94%, and 85% had at least five courses of chemotherapy. The median follow-up time for all patients was 50 months. The 3-year local progression-free survival (LPFS) was 70% in the SD arm versus 73% in the HD arm (not significant). The LPFS for SCC and AC was 75% versus 79% and 61% versus 61% for SD and HD, respectively (not significant). The 3-year locoregional progression-free su...Continue Reading
References
May 11, 1999·JAMA : the Journal of the American Medical Association·J S CooperL L Leichman
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D MinskyDavid P Kelsen
Apr 21, 2007·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Shaleen KumarPunita Lal
Oct 29, 2010·International Journal of Radiation Oncology, Biology, Physics·Mitchell MachtayWalter J Curran
Dec 3, 2010·International Journal of Radiation Oncology, Biology, Physics·James WelshRitsuko Komaki
May 9, 2012·Cancer·James WelshJaffer A Ajani
Jun 1, 2012·The New England Journal of Medicine·P van HagenUNKNOWN CROSS Group
Aug 14, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Y B TeohE K W Ng
Sep 7, 2013·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·R L G M BlomM I van Berge Henegouwen
Apr 15, 2014·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·E VersteijneM C C M Hulshof
Aug 4, 2015·Expert Review of Anticancer Therapy·Tao SongShixiu Wu
Nov 5, 2015·International Journal of Radiation Oncology, Biology, Physics·Kosj YamoahNitin Ohri
Oct 16, 2016·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hyun Ju KimChang Geol Lee
Nov 22, 2016·International Journal of Radiation Oncology, Biology, Physics·Jeffrey V BrowerAndrew M Baschnagel
Aug 28, 2018·Cancer Management and Research·Wei ZhangSheng-Bin Dai
Sep 7, 2018·Scientific Reports·Aafke CreemersHanneke W M van Laarhoven
Dec 31, 2019·World Journal of Gastroenterology : WJG·Judith de Vos-GeelenValery Epp Lemmens
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J HoningG A P Hospers
Citations
Aug 26, 2021·Clinical and Translational Radiation Oncology·Tatsuya SuwaTakashi Mizowaki
Sep 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yun-Hsuan LinYu-Ming Wang
Sep 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maarten C C M HulshofUNKNOWN ARTDECO study group
Sep 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph PöttgenMartin Stuschke
Oct 26, 2021·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Ronald ChowSangjune Laurence Lee